The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome

Change From Baseline in Postprandial TG Area Under the Curve (AUC)(0-9h)

Participants had 2 postprandial assessments - one at Baseline (completed at least 48 hours prior to first dose) and one at any time between Week 13 and 19, inclusive. Assessment timepoints include from 1-hr before to up to 9 hrs after ingestion of the meal at 1-hour interval. Postprandial AUC results were calculated using a linear trapezoidal rule for each postprandial measure in the subset of participants who had postprandial assessments 0-9 hour results at baseline and the postbaseline between Week 13 to 19.

Time frame: Baseline to an on-treatment assessment between Week 13 and Week 19

Absolute Change From Baseline in Fasting TG at Month 3

The Month 3 endpoint was defined as the average of Week 12 (Day 78) and Week 13 (Day 85) fasting assessments.

Time frame: Baseline to 3 months

Treatment Response Rate Defined as Participants With Fasting Plasma TG < 750 mg/dL at Month 3

The Month 3 endpoint was defined as the average of Week 12 (Day 78) and Week 13 (Day 85) fasting assessments. mg/dL = milligrams per deciliter

Time frame: Baseline to 3 months

Treatment Response Rate Defined as Participants With Fasting TG ≥ 40% Reduction From Baseline at Month 3

The Month 3 endpoint was defined as the average of Week 12 (Day 78) and Week 13 (Day 85) fasting assessments.

Time frame: Baseline to 3 months

Frequency and Severity of Participant-reported Abdominal Pain During the Treatment Period